ESSA Pharma (EPIX) Stock Price, News & Analysis

Company Overview

ESSA Pharma is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies that target KCNQ potassium ion channels, which play a critical role in the regulation of neuronal excitability. The company’s research focuses on rare neurological and neurodevelopmental disorders driven by dysfunction in these channels. By leveraging proprietary small-molecule chemistry, ESSA Pharma aims to address underlying disease mechanisms rather than merely treating symptoms.

The company’s lead candidate, EPI-589, is an orally delivered small molecule designed to upregulate KCNQ channel activity. EPI-589 is currently being evaluated in clinical trials for Temple-Baraitser syndrome and KCNQ2 developmental and epileptic encephalopathy, two ultra-rare genetic conditions characterized by severe seizures, developmental delays and motor impairments. In addition to EPI-589, ESSA Pharma maintains a preclinical pipeline of novel modulators intended to expand its portfolio into other disorders linked to KCNQ dysfunction.

Founded in Canada and headquartered in Vancouver, ESSA Pharma conducts its research and clinical programs across North America and Europe. The company collaborates with leading academic institutions and patient advocacy groups to design trials that address the unique challenges of rare disease studies, including small patient populations and high unmet medical need.

ESSA Pharma is led by a management team with deep expertise in neuroscience drug development, translational research and regulatory strategy. The company is publicly traded on the Nasdaq Stock Market under the ticker symbol EPIX and is committed to advancing precision therapies that have the potential to transform outcomes for patients living with rare neurological disorders.

Key Stats

• Today's Range: $0.20 to $0.20
• 50-Day Range: $0.19 to $0.24
• 52-Week Range: $0.18 to $1.94
• Volume: N/A
• Average Volume: 3.75 million shs
• Market Capitalization: $9.52 million
• P/E Ratio: N/A
• Dividend Yield: 839.96%
• Price Target: N/A
• Consensus Rating: Sell

Company Calendar

• Last Earnings: 8/13/2025
• Today: 7/11/2026
• Fiscal Year End: 9/30/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:EPIX
• CIK: 1633932
• Web: www.essapharma.com
• Phone: 778-331-0962
• Fax: 604-738-4080
• Employees: 50
• Year Founded: 2009

Profitability

• EPS (Trailing Twelve Months): ($0.56)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$28.54 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -21.71%
• Return on Assets: -21.22%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 69.06
• Quick Ratio: 69.06

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.81 per share
• Price / Book: 0.07

Miscellaneous

• Outstanding Shares: 47,308,000
• Free Float: 39,975,000
• Market Cap: $9.52 million
• Optionable: Optionable
• Beta: 1.57